217 related articles for article (PubMed ID: 32494691)
21. COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms.
Ostaszewski M; Mazein A; Gillespie ME; Kuperstein I; Niarakis A; Hermjakob H; Pico AR; Willighagen EL; Evelo CT; Hasenauer J; Schreiber F; Dräger A; Demir E; Wolkenhauer O; Furlong LI; Barillot E; Dopazo J; Orta-Resendiz A; Messina F; Valencia A; Funahashi A; Kitano H; Auffray C; Balling R; Schneider R
Sci Data; 2020 May; 7(1):136. PubMed ID: 32371892
[TBL] [Abstract][Full Text] [Related]
22. Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients.
Iturrieta-Zuazo I; Rita CG; García-Soidán A; de Malet Pintos-Fonseca A; Alonso-Alarcón N; Pariente-Rodríguez R; Tejeda-Velarde A; Serrano-Villar S; Castañer-Alabau JL; Nieto-Gañán I
Clin Immunol; 2020 Oct; 219():108572. PubMed ID: 32810602
[TBL] [Abstract][Full Text] [Related]
23. Hypotension, Systemic Inflammatory Response Syndrome, and COVID-19: A Clinical Conundrum.
Hanidziar D; Bittner EA
Anesth Analg; 2020 Sep; 131(3):e175-e176. PubMed ID: 32541247
[No Abstract] [Full Text] [Related]
24. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.
Park A; Iwasaki A
Cell Host Microbe; 2020 Jun; 27(6):870-878. PubMed ID: 32464097
[TBL] [Abstract][Full Text] [Related]
25. Synergistic antiviral effects against SARS-CoV-2 by plant-based molecules.
Prasad A; Muthamilarasan M; Prasad M
Plant Cell Rep; 2020 Sep; 39(9):1109-1114. PubMed ID: 32561979
[TBL] [Abstract][Full Text] [Related]
26. Could the Induction of Trained Immunity by β-Glucan Serve as a Defense Against COVID-19?
Geller A; Yan J
Front Immunol; 2020; 11():1782. PubMed ID: 32760409
[TBL] [Abstract][Full Text] [Related]
27. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.
Encinar JA; Menendez JA
Viruses; 2020 May; 12(5):. PubMed ID: 32397643
[TBL] [Abstract][Full Text] [Related]
28. COVID-19 antibodies on trial.
DeFrancesco L
Nat Biotechnol; 2020 Nov; 38(11):1242-1252. PubMed ID: 33087898
[TBL] [Abstract][Full Text] [Related]
29. High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects.
Liu X; Cao W; Li T
Front Immunol; 2020; 11():1660. PubMed ID: 32760407
[TBL] [Abstract][Full Text] [Related]
30. COVID-19, severe asthma, and biologics.
García-Moguel I; Díaz Campos R; Alonso Charterina S; Fernández Rodríguez C; Fernández Crespo J
Ann Allergy Asthma Immunol; 2020 Sep; 125(3):357-359.e1. PubMed ID: 32553608
[No Abstract] [Full Text] [Related]
31. Crosstalk Between Platelets and Microbial Pathogens.
Li C; Li J; Ni H
Front Immunol; 2020; 11():1962. PubMed ID: 32849656
[TBL] [Abstract][Full Text] [Related]
32. Mechanistic inferences from clinical reports of SARS-CoV-2.
Jenkins MM; McCaw TR; Goepfert PA
Infect Dis (Lond); 2020 Aug; 52(8):527-537. PubMed ID: 32459123
[TBL] [Abstract][Full Text] [Related]
33. [Narrative review of the immune response against coronavirus: An overview, applicability for SARS-COV-2, and therapeutic implications].
García-Salido A
An Pediatr (Engl Ed); 2020 Jul; 93(1):60.e1-60.e7. PubMed ID: 32439309
[TBL] [Abstract][Full Text] [Related]
34. Silencing of immune activation with methotrexate in patients with COVID-19.
Safavi F; Nath A
J Neurol Sci; 2020 Aug; 415():116942. PubMed ID: 32471659
[No Abstract] [Full Text] [Related]
35. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns.
Sette A; Crotty S
Nat Rev Immunol; 2020 Aug; 20(8):457-458. PubMed ID: 32636479
[TBL] [Abstract][Full Text] [Related]
36. Sars-CoV-2 in pregnancy: Why is it better than expected?
Ghi T; di Pasquo E; Mekinian A; Calza L; Frusca T
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():476-478. PubMed ID: 32739606
[TBL] [Abstract][Full Text] [Related]
37. The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis.
Wessels I; Rolles B; Rink L
Front Immunol; 2020; 11():1712. PubMed ID: 32754164
[TBL] [Abstract][Full Text] [Related]
38. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.
Blanco-Melo D; Nilsson-Payant BE; Liu WC; Uhl S; Hoagland D; Møller R; Jordan TX; Oishi K; Panis M; Sachs D; Wang TT; Schwartz RE; Lim JK; Albrecht RA; tenOever BR
Cell; 2020 May; 181(5):1036-1045.e9. PubMed ID: 32416070
[TBL] [Abstract][Full Text] [Related]
39. Sequence homology between human PARP14 and the SARS-CoV-2 ADP ribose 1'-phosphatase.
Webb TE; Saad R
Immunol Lett; 2020 Aug; 224():38-39. PubMed ID: 32534867
[TBL] [Abstract][Full Text] [Related]
40. Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies.
Zhou T; Su TT; Mudianto T; Wang J
J Exp Med; 2020 Oct; 217(10):. PubMed ID: 32910820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
